142 related articles for article (PubMed ID: 36830885)
1. Tocilizumab in Combination with Corticosteroids in COVID-19 Pneumonia: A Single-Centre Retrospective Controlled Study.
Kardos Z; Szabó M; Baráth Z; Miksi Á; Oláh C; Kozma Á; Gergely JA; Csánky E; Szekanecz Z
Biomedicines; 2023 Jan; 11(2):. PubMed ID: 36830885
[No Abstract] [Full Text] [Related]
2. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
3. Benefits of Tocilizumab in patients with a severe form of SARS-CoV-2 infection: Experience of the intensive care unit of the Mohammed VI university hospital, Oujda.
El Rhalete A; Rhazi I; Bensaid A; Diass S; Kaouini A; Ounci E; Abdi M; Maarad M; Babouh C; Alami Z; Abda N; Bkiyer H; Housni B
Ann Med Surg (Lond); 2021 Jul; 67():102514. PubMed ID: 34221397
[TBL] [Abstract][Full Text] [Related]
4. Appropriate use of tocilizumab in COVID-19 infection.
Keske Ş; Tekin S; Sait B; İrkören P; Kapmaz M; Çimen C; Uğur S; Çelebi İ; Bakır VO; Palaoğlu E; Şentürk E; Çağlayan B; Çakar N; Tabak L; Ergönül Ö
Int J Infect Dis; 2020 Oct; 99():338-343. PubMed ID: 32726724
[TBL] [Abstract][Full Text] [Related]
5. A single-center experience of early administration of tocilizumab and corticosteroids in patients with COVID-19 pneumonia.
Milošević I; Barać A; Jovanović J; Vujović A; Stevanović G; Todorović N; Milošević B
Trans R Soc Trop Med Hyg; 2023 Sep; 117(9):668-672. PubMed ID: 37103332
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic efficacy, mechanical ventilation, length of hospital stay, and mortality rate in severe COVID-19 patients treated with tocilizumab.
Sarhan RM; Madney YM; Abou Warda AE; Boshra MS
Int J Clin Pract; 2021 Jun; 75(6):e14079. PubMed ID: 33550688
[TBL] [Abstract][Full Text] [Related]
7. Biomarker variation in patients successfully treated with tocilizumab for severe coronavirus disease 2019 (COVID-19): results of a multidisciplinary collaboration.
Conrozier T; Lohse A; Balblanc JC; Dussert P; Royer PY; Bossert M; Bozgan AM; Gendrin V; Charpentier A; Toko L; Badie J; Mezher C; Roux MF; Kadiane-Oussou NJ; Contreras R; Kessler J; Mazurier I; Klopfenstein T; Zayet S
Clin Exp Rheumatol; 2020; 38(4):742-747. PubMed ID: 32573419
[TBL] [Abstract][Full Text] [Related]
8. Tocilizumab therapy for severely-ill COVID-19 pneumonia patients: a single-centre retrospective study.
Iqtadar S; Khan A; Mumtaz SU; Pascual-Figal DA; Livingstone S; Abaidullah S
J Physiol Pharmacol; 2022 Aug; 73(4):. PubMed ID: 36696245
[TBL] [Abstract][Full Text] [Related]
9. Severity and prognostic factors of SARS-CoV-2-induced pneumonia: The value of clinical and laboratory biomarkers and the A-DROP score.
Szabó M; Kardos Z; Oláh C; Tamáska P; Hodosi K; Csánky E; Szekanecz Z
Front Med (Lausanne); 2022; 9():920016. PubMed ID: 35935801
[TBL] [Abstract][Full Text] [Related]
10. Low-dose subcutaneous tocilizumab to prevent disease progression in patients with moderate COVID-19 pneumonia and hyperinflammation.
Potere N; Di Nisio M; Rizzo G; La Vella M; Polilli E; Agostinone A; Spacone A; Di Carlo S; Costantini A; Abbate A; Porreca E; Parruti G
Int J Infect Dis; 2020 Nov; 100():421-424. PubMed ID: 32768701
[TBL] [Abstract][Full Text] [Related]
11. Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial.
Caballero Bermejo AF; Ruiz-Antorán B; Fernández Cruz A; Diago Sempere E; Callejas Díaz A; Múñez Rubio E; Avendaño-Solá C; Ramos Martínez A; Sancho López A;
Trials; 2020 Sep; 21(1):794. PubMed ID: 32938496
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Tocilizumab in Management of COVID-19 Patients Admitted to Intensive Care Units: A Multicenter Retrospective Cohort Study.
Ibrahem HY; Aly DH; Warda AEA; Farahat RA; Youssef RM; Abdelhamid MH; Goud HA; Mohamed RR; Eldien MAYN; Alotaibi FO; Alzarea AI; Alanazi AS; Eisa NM; Refaee AS
Medicina (Kaunas); 2022 Dec; 59(1):. PubMed ID: 36676678
[No Abstract] [Full Text] [Related]
13. Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study.
Moreno-Pérez O; Andres M; Leon-Ramirez JM; Sánchez-Payá J; Rodríguez JC; Sánchez R; García-Sevila R; Boix V; Gil J; Merino E
J Autoimmun; 2020 Nov; 114():102523. PubMed ID: 32690352
[TBL] [Abstract][Full Text] [Related]
14. The Use of Corticosteroids or Tocilizumab in COVID-19 Based on Inflammatory Markers.
Rubio-Rivas M; Mora-Luján JM; Montero A; Aguilar García JA; Méndez Bailón M; Fernández Cruz A; Oriol I; Teigell-Muñoz FJ; Dendariena Borque B; De la Peña Fernández A; Fernández González R; Gil Sánchez R; Fernández Fernández J; Catalán M; Cortés-Rodríguez B; Mella Pérez C; Montero Rivas L; Suárez Fuentetaja R; Ternero Vega JE; Ena J; Martin-Urda Díez-Canseco A; Pérez García C; Varona JF; Casas-Rojo JM; Millán Núñez-Cortés J;
J Gen Intern Med; 2022 Jan; 37(1):168-175. PubMed ID: 34664188
[TBL] [Abstract][Full Text] [Related]
15. Administration Timing and Efficacy of Tocilizumab in Patients With COVID-19 and Elevated IL-6.
Li P; Lu Z; Li Q; Wang Z; Guo Y; Cai C; Wang S; Liu P; Su X; Huang Y; Dong Y; Qiu W; Ling Y; Yarmus L; Luo F; Zeng L; Bai C; Zhang W
Front Mol Biosci; 2021; 8():651662. PubMed ID: 33937333
[TBL] [Abstract][Full Text] [Related]
16. Treatment Outcomes of Tocilizumab in Critically-Ill COVID-19 Patients, Single-Centre Retrospective Study.
Hafez W; Ziade MA; Arya A; Saleh H; Abdelshakor M; Fadl Alla O; Agrawal P; Ali S; Rao SR; Gupta S; Abdelli I; Sebastian H; Ali M; Gador M; Al Baha Z; Abdelrahman A
Antibiotics (Basel); 2022 Feb; 11(2):. PubMed ID: 35203844
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of the early treatment with tocilizumab-hydroxychloroquine and tocilizumab-remdesivir in severe COVID-19 Patients.
Sarhan RM; Harb HS; Abou Warda AE; Salem-Bekhit MM; Shakeel F; Alzahrani SA; Madney YM; Boshra MS
J Infect Public Health; 2022 Jan; 15(1):116-122. PubMed ID: 34764044
[TBL] [Abstract][Full Text] [Related]
18. Observational study on off-label use of tocilizumab in patients with severe COVID-19.
Albertini L; Soletchnik M; Razurel A; Cohen J; Bidegain F; Fauvelle F; Safrano G; Piquet J; Maurer C; Goldgran-Toledano D
Eur J Hosp Pharm; 2021 Jan; 28(1):22-27. PubMed ID: 32912961
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy of Tocilizumab and steroid for management of COVID-19 associated cytokine release syndrome: A single center experience from Pune, Western India.
Dravid A; Kashiva R; Khan Z; Memon D; Kodre A; Potdar P; Mane M; Borse R; Pawar V; Patil D; Banerjee D; Bhoite K; Pharande R; Kalyani S; Raut P; Bapte M; Mehta A; Reddy MS; Bhayani K; Laxmi SS; Vishnu PD; Srivastava S; Khandelwal S; More S; Shinde R; Pawar M; Harshe A; Kadam S; Mahajan U; Joshi G; Mane D
Medicine (Baltimore); 2021 Jul; 100(29):e26705. PubMed ID: 34398044
[TBL] [Abstract][Full Text] [Related]
20. Beneficial and harmful outcomes of tocilizumab in severe COVID-19: A systematic review and meta-analysis.
Rubio-Rivas M; Forero CG; Mora-Luján JM; Montero A; Formiga F; Homs NA; Albà-Albalate J; Sánchez L; Rello J; Corbella X
Pharmacotherapy; 2021 Nov; 41(11):884-906. PubMed ID: 34558742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
